在本临床研究中,研究人员测试了溶瘤腺病毒Delta24-RGD在复发胶质母细胞瘤患者中的应用。这种腺病毒的独特之处在于,其无法在正常细胞中复制,但可以在Rb通路失活的细胞中复制。而此信号通路在超过90%的胶质瘤中失活,这使得溶瘤腺病毒Delta24...
Interestingly, Delta-24-RGD treatment led to the downregulation of relevant DNA damage repair proteins, further sensitizing tumors cells to the effect of radiotherapy. Additionally, Delta-24-RGD/radiotherapy treatment significantly increased the trafficking of immune cells (CD3, CD4+ and CD8+) to the...
However, both Ad5-delta-24-RGD4C and Ad5-delta-24-RGD2C2G were equally effective in the murine immunocompetent CT-2A glioma model due to a primary role of antitumor immune responses in the therapeutic efficacy of oncolytic virotherapy.
Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells： role of aut 维普资讯 http://www.cqvip.com
As part of a phase 1, dose-escalation, biological-endpoint clinical study (NCT00805376) of DNX-2401 (Delta-24-RGD), a Rb-targeted, tumor-selective, replication-competent oncolytic adenovirus, conducted in 37 patients with recurrent malignant glioma, 12 patients received an intratumoral injection th...
textabstractBackground: A phase I/II trial for glioblastoma with the oncolytic adenovirus Delta24-RGD was recently completed. Delta24-RGD conditionally replicates in cells with a disrupted retinoblastomapathway and enters cells via αvβ3/5 integrins. Glioblastomas are differentially sensitive to Delta...
Here we investigate the effect of Delta-24-RGD oncolytic adenovirus on innate and adaptive anti-glioma immunity. Design: Mouse GL261-glioma model was set up in immunocompetent C57BL/6 mouse for Delta-24-RGD treatment. The changes of the immune cell populations were analyzed by ...
Delta-24-RGD is a replication competent adenovirus engineered to replicate in tumor cells with an aberrant RB pathway. This virus has proven to be safe and effective in adult gliomas. Here we report that the administration of Delta-24-RGD is safe in mice and results in a significant increase...
First-in- human phase I clinical trial of oncolytic delta-24-rgd (dnx-2401) with biological end- points: Implications for viro-immunotherapy. Neuro-Oncology. 2014;16(Suppl 3):iii39. DOI: 10.1093/neuonc/nou208.61Lang FF, Conrad C, Gomez-Manzano C, Tufaro F, Yung W, Sawaya R, et al...
Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: Role of autophagic cell death J Natl Cancer Inst 2007 ;99.Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F, Xu J, Kondo Y, Bekele BN, Colman H, et al: Examination of the ...